Nitin Roper MD

191 posts

Nitin Roper MD

Nitin Roper MD

@nitinroper

Physician-Scientist Early Investigator and Thoracic Oncologist at the NCI. All views and tweets are my own and do not reflect those of the NIH or government.

Bethesda, Maryland Katılım Aralık 2009
156 Takip Edilen187 Takipçiler
Nitin Roper MD
Nitin Roper MD@nitinroper·
@MontessaLee Hi Montessa - I am a lung cancer researcher at the NCI in Bethesda, MD. Would you be willing to assist as an advocate for a career development award grant in SCLC? If so, please email me at nitin.roper@nih.gov. Many thanks for your consideration.
English
0
0
1
0
Nitin Roper MD
Nitin Roper MD@nitinroper·
In science we depend on @FedEx to safely and quickly move reagents between labs (even during the pandemic). We have yet to receive a valuable, overnight package after 3 days. Can @FedExHelp provide some help?
English
2
0
3
0
Nitin Roper MD
Nitin Roper MD@nitinroper·
New postdoctoral position is available in my laboratory to study neuroendocrine tumor immunology using novel patient-derived organoids and translational studies in upcoming clinical trials with @JaydiDelRivero tinyurl.com/j2j59w28
English
0
3
5
0
Nitin Roper MD
Nitin Roper MD@nitinroper·
Excited to attend the upcoming Forbeck meeting "Neuroendocrine Cell Fate in Development and Cancer" and learn from the top experts in the field
English
1
0
6
0
Nitin Roper MD
Nitin Roper MD@nitinroper·
@chulkimMD @drgandara @drgandara @chulkimMD 2 explanations - 1. MET amp is a subclonal resistance mechanism (spatial heterogeneity) and 2. MET amp appears at first or second osi progression (temporal heterogeneity). Pts with longer response to osi did not evidence of MET amp
English
0
4
9
0
Chul Kim
Chul Kim@chulkimMD·
@drgandara Thank you @drgandara. What we found was that MET amplification was subclonal and there was spatial heterogeneity. I think multi-region sequencing that we utilized helped picked up more MET amplification events. Nitin @nitinroper, further thoughts on Dr. Gandara's comment?
English
1
1
7
0
Nitin Roper MD
Nitin Roper MD@nitinroper·
Check out our paper taking a deep dive into EGFR mutant lung cancer resistance mechanisms in very first issue of @CellRepMed. This was translational research at its best, a collaborative effort of medical/radiation oncology, surgery and bioinformatics. cell.com/cell-reports-m…
English
3
2
5
0
Nitin Roper MD retweetledi
AL Brown
AL Brown@annaleighbrown2·
Whoo!! Our paper using multi-region phylogeny to explore the resistance mechanisms of EGFR mutant lung cancer is out! I'm really proud of the work we put into this and it's great to see it out in the world and in the very first issue of @CellRepMed cell.com/cell-reports-m…
English
0
4
21
0
Nitin Roper MD
Nitin Roper MD@nitinroper·
Percentage of precision cancer medicine trials in the U.S. has increased from 3% in 2006 to 16% in 2013. #ASCO14
Nitin Roper MD tweet media
English
0
0
0
0
Nitin Roper MD retweetledi
Jennifer Ersek
Jennifer Ersek@JLErsek·
Percentage of #precisionmedicine trials in the U.S. has increased from 3% in 2006 to 16% in 2013. Roper et al. Abstract number 1547 #LCI
English
0
1
0
0
Nitin Roper MD
Nitin Roper MD@nitinroper·
Future of precision cancer medicine will be large clinical registries such as Cancer LinQ, not randomized trials. - Dr. Schilsky #ASCO14
English
0
1
0
0
Nitin Roper MD
Nitin Roper MD@nitinroper·
How Germany, unlike the U.S., creates a competitive market for prescription drugs. bit.ly/1pgZ1Hd
English
0
0
0
0

Keşfet

@MontessaLee @dustywater @KHigginsMD @lcfamerica @FedEx @FedExHelp @JaydiDelRivero @NatureComms